Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity - USD ($)		Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		83,964,569
Balance at Dec. 31, 2016		$ 10,189,973		$ 1,205,456	$ (7,561,028)	$ 3,834,401
Stock issuance for services (in shares)		43,613
Stock issuance for services		$ 45,000				45,000
Stock issuance for financing, net of costs (in shares)		4,405,373
Stock issuance for financing, net of costs		$ 6,516,650				6,516,650
Stock-based compensation				837,531		$ 837,531
Stock issued due to exercise of options (in shares)		925,000				925,000
Stock issued due to exercise of options		$ 130,354		(30,156)		$ 100,198
Net loss for the period					(5,501,788)	(5,501,788)
Balance (in shares) at Sep. 30, 2017		89,338,555
Balance at Sep. 30, 2017		$ 16,881,977		2,012,831	(13,062,816)	5,831,992
Balance (in shares) at Dec. 31, 2017		90,225,869
Balance at Dec. 31, 2017		$ 18,244,659		1,768,526	(15,626,100)	4,387,085
Stock issuance for services (in shares)	[1]	641,717
Stock issuance for services		$ 1,238,513	[1]			1,238,513
Stock issuance for financing, net of costs (in shares)	[2]	1,861,627
Stock issuance for financing, net of costs		$ 3,966,362	[2]			3,966,362
Stock-based compensation				7,288		$ 7,288
Stock issued due to exercise of options (in shares)		1,866,996				1,866,996
Stock issued due to exercise of options		$ 1,923,922		(386,898)		$ 1,537,024
Net loss for the period					(8,226,005)	(8,226,005)
Balance (in shares) at Sep. 30, 2018		94,596,209
Balance at Sep. 30, 2018		$ 25,373,456		$ 1,388,916	$ (23,852,105)	$ 2,910,267

[1] On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.

[2] On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.